Biostatistics and Bioinformatics Department Metrics

View the grants and publications from the Department of Biostatistics and Bioinformatics.

Grants
  • Moffitt Imaging Biomarker Validation Center
    Sponsor: Nat Institutes of Health
    PI (Contact):Lee, J.,PI:Gillies, R.,PI:Heine, J.,PI:Schabath, M.
  • (00007009) Mechanisms of Radioresistance and Strategies for Radiosensitization in OCCC
    Sponsor: Nat Institutes of Health
    PI:Mo, Q.
  • Tumor and Metastatic Collagen Microenvironments: Divergent Targeting Approaches
    Sponsor: Nat Institutes of Health
    PI:Mo, Q.
  • A Vicious Cycle of Pyroptotic Cancer Cells and Fibroblasts Fuels Chemoresistance
    Sponsor: Nat Institutes of Health
    PI:Mo, Q.
  • Curated Prostate Cancer Data for Novel and Reproducible Prognostic Modeling
    Sponsor: Nat Institutes of Health
    PI:Fridley, B.
  • Adrenergic Signaling Inhibition to Enhance the Immunogenecity of the Ovarian Tumor Microenvironment Prior to PD-1 Checkpoint Therapy
    Sponsor: Nat Institutes of Health
    PI:Chen, D.
  • Targeting Tumor Repopulation and the Immune Microenvironment to Overcome Chemoresistance
    Sponsor: Nat Institutes of Health
    PI:Mo, Q.
  • Decoding Tobacco-Related Oral Cancer Ecosystem by Integrative Approach
    Sponsor: Nat Institutes of Health
    PI (Contact):Tan, A.,PI (MPI):Chung, C.
  • Investigating the prognostic role of intrinsic immune evasion mechanisms in HNSCC
    Sponsor: Nat Institutes of Health
    PI:Wang, X.
  • Barriers to Screening Breast MRI Utilization among Patients at Elevated Risk (B-SUPER)
    Sponsor: Breast Cancer Research Fdtn
    PI:Brownstein, N.
  • Reduction of Lethal Prostate Cancer Disparities in Underserved Hispanic/Latino Populations
    Sponsor: US Army
    PI:Teer, J.
  • Tampa Bay Life Sciences Computing Commons (TBLSCC)
    Sponsor: Nat Institutes of Health
    PI:Eschrich, S.
  • AOST-1822, Protocol OST31-164-01, An Open-Label Phase 2 Study of Maintenance Therapy with OST31-164 After Resection with Recurrent Osteosarcoma
    Sponsor: Children's Oncology Group
    PI:Fridley, B.
  • Research Digital Slide Archive for Immunohistochemical Staining and Tissue Microarray Applications
    Sponsor: Moffitt Fdtn
    PI:Eschrich, S.,CO-PI:Johnson, J.
  • Research Digital Slide Archive for Immunohistochemical Staining and Tissue Microarray Applications
    Sponsor: Moffitt Cancer Center
    PI:Eschrich, S.,CO-PI:Johnson, J.
Publications
  • Reblin M, Wells KJ, Otto A, McCormick R, Rodriguez L, Walters K, Sutton SK, Zebrack B, Forsyth P, Byrne MM. Addressing a critical need for caregiver support in neuro-oncology: development of a caregiver navigation intervention using eSNAP social resource visualization. Support Care Cancer. 2022 Jun.30(6):5361-5370. Pubmedid: 35290512. Pmcid: PMC8922391.
  • Anadon CM, Yu X, Hänggi K, Biswas S, Chaurio RA, Martin A, Payne KK, Mandal G, Innamarato P, Harro CM, Mine JA, Sprenger KB, Cortina C, Powers JJ, Costich TL, Perez BA, Gatenbee CD, Prabhakaran S, Marchion D, Heemskerk MHM, Curiel TJ, Anderson AR, Wenham RM, Rodriguez PC, Conejo-Garcia JR. Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells. Cancer Cell. 2022 May.40(5):545-557.e13. Pubmedid: 35427494. Pmcid: PMC9096229.
  • Christy SM, Sutton SK, Abdulla R, Boxtha C, Gonzalez P, Cousin L, Ewing A, Montoya S, Lopez D, Beehler T, Sanchez J, Carvajal R, Meade CD, Gwede CK. A multilevel, low literacy dual language intervention to promote colorectal cancer screening in community clinics in Florida: A randomized controlled trial. Prev Med. 2022 May.158:107021. Pubmedid: 35305995. Pmcid: PMC9018599.
  • Song X, Chang S, Seminario-Vidal L, de Mingo Pulido A, Tordesillas L, Song X, Reed RA, Harkins A, Whiddon S, Nguyen JV, Moran Segura C, Zhang C, Yoder S, Sayegh Z, Zhao Y, Messina JL, Harro CM, Zhang X, Conejo-Garcia JR, Berglund AE, Sokol L, Zhang J, Rodriguez PC, Mule JJ, Futreal AP, Tsai KY, Chen PL. Genomic and Single-Cell Landscape Reveals Novel Drivers and Therapeutic Vulnerabilities of Transformed Cutaneous T-cell Lymphoma. Cancer Discov. 2022 May.12(5):1294-1313. Pubmedid: 35247891.
  • Li J, Smalley I, Chen Z, Wu JY, Phadke MS, Teer JK, Nguyen T, Karreth FA, Koomen JM, Sarnaik AA, Zager JS, Khushalani NI, Tarhini AA, Sondak VK, Rodriguez PC, Messina JL, Chen YA, Smalley KSM. Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy. Clin Cancer Res. 2022 May.28(10):2131-2146. Pubmedid: 35247927. Pmcid: PMC9106889.
  • Peres LC, Colin-Leitzinger C, Sinha S, Marks JR, Conejo-Garcia JR, Alberg AJ, Bandera EV, Berchuck A, Bondy ML, Christensen BC, Cote ML, Doherty JA, Moorman PG, Peters ES, Moran Segura C, Nguyen JV, Schwartz AG, Terry PD, Wilson CM, Fridley BL, Schildkraut JM. Racial Differences in the Tumor Immune Landscape and Survival of Women with High-Grade Serous Ovarian Carcinoma. Cancer Epidemiol Biomarkers Prev. 2022 May.31(5):1006-1016. Pubmedid: 35244678. Pmcid: PMC9081269.
  • Yu X, Cen L, Chen YA, Markowitz J, Shaw TI, Tsai KY, Conejo-Garcia JR, Wang X. Tumor Expression Quantitative Trait Methylation Screening Reveals Distinct CpG Panels for Deconvolving Cancer Immune Signatures. Cancer Res. 2022 May.82(9):1724-1735. Pubmedid: 35176128. Pmcid: PMC9064917.
  • Tan ES, Knepper TC, Wang X, Permuth JB, Wang L, Fleming JB, Xie H. Copy Number Alterations as Novel Biomarkers and Therapeutic Targets in Colorectal Cancer. Cancers (Basel). 2022 Apr.14(9). Pubmedid: 35565354. Pmcid: PMC9101426.
  • Yang MJ, Yepez VV, Brandon KO, Reblin M, Pidala J, Jim HSL, Meyer JS, Gore LR, Khera N, Lau P, Sauls RM, Jones SR, Vinci C. A mindfulness-based stress management program for caregivers of allogeneic hematopoietic stem cell transplant (HCT) patients: Protocol for a randomized controlled trial. PLoS One. 2022 Apr.17(4):e0266316. Pubmedid: 35363799. Pmcid: PMC8975158.
  • Mahajan S, Majumder A, Stewart PA, Chen YA, Adhikari E, Fang B, Yang Y, Lawrence H, Kinose F, Koomen JM, Haura EB. Deubiquitinase Vulnerabilities Identified through Activity-Based Protein Profiling in Non-Small Cell Lung Cancer. Acs Chem Biol. 2022 Apr.17(4):776-784. Pubmedid: 35311290.
  • Jain MD, Ziccheddu B, Coughlin CA, Faramand RG, Griswold AJ, Reid KM, Menges M, Zhang Y, Cen L, Wang X, Hussaini MO, Landgren O, Davila ML, Schatz JH, Locke FL, Maura F. Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma. Blood. 2022 Apr. Pubmedid: 35476848.
  • Lake PW, Conley CC, Pal T, Sutton SK, Vadaparampil ST. Anxiety and depression among Black breast cancer survivors: Examining the role of patient-provider communication and cultural values. Patient Educ Couns. 2022 Apr. Pubmedid: 35440374.
  • Wood AC, Zhang Y, Mo Q, Cen L, Fontaine J, Hoffe SE, Frakes J, Dineen SP, Pimiento JM, Walko CM, Mehta R. Evaluation of Tumor DNA Sequencing Results in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma Stratified by TP53 Mutation Status. Oncologist. 2022 Apr.27(4):307-313. Pubmedid: 35380714. Pmcid: PMC8982441.
  • Medina-Ramirez P, Casas L, Sutton SK, Calixte-Civil P, Brandon KO, Martinez U, Meade CD, Byrne MM, Brandon TH, Simmons VN. Hispanic/Latinx ethnic subgroup differences in sociodemographic, sociocultural, and smoking characteristics in a cessation trial: An exploratory study. Nicotine Tob Res. 2022 Apr. Pubmedid: 35366328.
  • Tan E, Whiting J, Knepper T, Xie H, Imanirad I, Carballido E, Felder S, Frakes J, Mo Q, Permuth JB, Somerer K, Kim R, Anaya DA, Fleming JB, Walko C, Sahin IH. Core Homologous Recombination Mutations and Improved Survival in Nonpancreatic GI Cancers. Am J Clin Oncol. 2022 Apr.45(4):137-141. Pubmedid: 35320814.
  • Liu X, Zhao B, Shaw TI, Fridley BL, Duckett DR, Tan AC, Teng M. Summarizing internal dynamics boosts differential analysis and functional interpretation of super enhancers. Nucleic Acids Res. 2022 Apr.50(6):3115-3127. Pubmedid: 35234924. Pmcid: PMC8989535.
  • Fernandez MR, Schaub FX, Yang C, Li W, Yun S, Schaub SK, Dorsey FC, Liu M, Steeves MA, Ballabio A, Tzankov A, Chen Z, Koomen JM, Berglund AE, Cleveland JL. Disrupting the MYC-TFEB Circuit Impairs Amino Acid Homeostasis and Provokes Metabolic Anergy. Cancer Res. 2022 Apr.82(7):1234-1250. Pubmedid: 35149590. Pmcid: PMC9004540.
  • Berglund A, Muenyi C, Siegel EM, Ajidahun A, Eschrich SA, Wong D, Hendrick LE, Putney RM, Kim S, Hayes DN, Shibata D. Characterization of Epigenomic Alterations in HPV16+ Head and Neck Squamous Cell Carcinomas. Cancer Epidemiol Biomarkers Prev. 2022 Apr.31(4):858-869. Pubmedid: 35064062. Pmcid: PMC8983563.
  • Majumder A, Hosseinian S, Stroud M, Adhikari E, Saller JJ, Smith MA, Zhang G, Agarwal S, Creixell M, Meyer BS, Kinose F, Bowers K, Fang B, Stewart PA, Welsh EA, Boyle TA, Meyer AS, Koomen JM, Haura EB. Integrated Proteomics-Based Physical and Functional Mapping of AXL Kinase Signaling Pathways and Inhibitors Define Its Role in Cell Migration. Mol Cancer Res. 2022 Apr.20(4):542-555. Pubmedid: 35022314. Pmcid: PMC8983558.
  • Chadha J, Adashek JJ, Jim H, Kim Y, Semaan A, Chakiryan NH, Safa H, Hajiran A, Sexton W, Gilbert SM, Manley BJ, Spiess PE, Chahoud J. Evaluation of Patient-Reported Outcomes (PROs) Protocol Content and Reporting for Clinical Trials that Lead to the approval of frontline Immune Checkpoint Blockade Combination for Patients with Advanced Renal Cell Carcinoma - The Patients' Voice or a Miss. Clin Genitourin Cancer. 2022 Apr.20(2):e158-e165. Pubmedid: 34974985.
  • Han G, Schell MJ, Reisenbichler ES, Guo B, Rimm DL. Determination of the number of observers needed to evaluate a subjective test and its application in two PD-L1 studies. Stat Med. 2022 Apr.41(8):1361-1375. Pubmedid: 34897773.
  • Yamoah K, Awasthi S, Mahal BA, Zhao SG, Grass GD, Berglund A, Abraham-Miranda J, Gerke T, Rounbehler RJ, Davicioni E, Liu Y, Park J, Cleveland JL, Pow-Sang JM, Fernandez D, Torres-Roca J, Karnes RJ, Schaeffer E, Freedland SJ, Spratt DE, Den RB, Rebbeck TR, Feng F. Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer. Eur Urol. 2022 Apr.81(4):325-330. Pubmedid: 33303244.
  • Vidrine JI, Shih YT, Businelle MS, Sutton SK, Hoover DS, Cottrell-Daniels C, Fennell BS, Bowles KE, Vidrine DJ. Comparison of an automated smartphone-based smoking cessation intervention versus standard quitline-delivered treatment among underserved smokers: protocol for a randomized controlled trial. BMC Public Health. 2022 Mar.22(1):563. Pubmedid: 35317789. Pmcid: PMC8939152.
  • Daniel Grass G, Alfonso JCL, Welsh E, Ahmed KA, Teer JK, Pilon-Thomas S, Harrison LB, Cleveland JL, Mulé JJ, Eschrich SA, Enderling H, Torres-Roca JF. The Radiosensitivity Index Gene Signature Identifies Distinct Tumor Immune Microenvironment Characteristics Associated With Susceptibility to Radiation Therapy. Int J Radiat Oncol Biol Phys. 2022 Mar. Pubmedid: 35289298.
  • Nikolos F, Hayashi K, Hoi XP, Alonzo ME, Mo Q, Kasabyan A, Furuya H, Trepel J, Di Vizio D, Guarnerio J, Theodorescu D, Rosser C, Apolo A, Galsky M, Chan KS. Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors. Nat Commun. 2022 Mar.13(1):1487. Pubmedid: 35347124. Pmcid: PMC8960844.
  • Chung CH, Li J, Steuer CE, Bhateja P, Johnson M, Masannat J, Poole MI, Song F, Hernandez-Prera JC, Molina H, Wenig BM, Kumar S, Kuperwasser C, Stephens PJ, Farinhas JM, Shin DM, Kish JA, Muzaffar J, Kirtane K, Rocco JW, Schell MJ, Saba NF, Bonomi M. Phase II multi-institutional clinical trial result of concurrent cetuximab and nivolumab in recurrent and/or metastatic head and neck squamous cell carcinoma. Clin Cancer Res. 2022 Mar. Pubmedid: 35344035.
  • Napoli M, Wu SJ, Gore BL, Abbas HA, Lee K, Checker R, Dhar S, Rajapakshe K, Tan AC, Lee MG, Coarfa C, Flores ER. Author Correction: ΔNp63 regulates a common landscape of enhancer associated genes in non-small cell lung cancer. Nat Commun. 2022 Mar.13(1):1717. Pubmedid: 35338160. Pmcid: PMC8956651.
  • Mitchell JR, Szepietowski P, Howard R, Reisman P, Jones JD, Lewis P, Fridley BL, Rollison DE. A Question-and-Answer System to Extract Data From Free-Text Oncological Pathology Reports (CancerBERT Network): Development Study. J Med Internet Res. 2022 Mar.24(3):e27210. Pubmedid: 35319481. Pmcid: PMC8987958.
  • Lee BD, Gitter A, Greene CS, Raschka S, Maguire F, Titus AJ, Kessler MD, Lee AJ, Chevrette MG, Stewart PA, Britto-Borges T, Cofer EM, Yu KH, Carmona JJ, Fertig EJ, Kalinin AA, Signal B, Lengerich BJ, Triche TJ, Boca SM. Ten quick tips for deep learning in biology. PLoS Comput Biol. 2022 Mar.18(3):e1009803. Pubmedid: 35324884. Pmcid: PMC8946751.
  • Mehta R, Frakes J, Kim J, Nixon A, Liu Y, Howard L, Martinez Jimenez ME, Carballido E, Imanirad I, Sanchez J, Dessureault S, Xie H, Felder S, Sahin I, Hoffe S, Malafa M, Kim R. Phase I Study of Lenvatinib and Capecitabine with External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma. Oncologist. 2022 Mar. Pubmedid: 35325225.
  • Yang M, Davis TB, Pflieger L, Nebozhyn MV, Loboda A, Wang H, Schell MJ, Thota R, Pledger WJ, Yeatman TJ. An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy. BMC Cancer. 2022 Mar.22(1):256. Pubmedid: 35272617. Pmcid: PMC8908604.
  • Tan E, Whiting J, Xie H, Imanirad I, Carballido E, Felder S, Frakes J, Mo Q, Walko C, Permuth JB, Sommerer K, Kim R, Anaya DA, Fleming JB, Sahin IH. BRAF Mutations Are Associated with Poor Survival Outcomes in Advanced-stage Mismatch Repair-deficient/Microsatellite High Colorectal Cancer. Oncologist. 2022 Mar.27(3):191-197. Pubmedid: 35274712. Pmcid: PMC8914499.
  • Giuliano AR, Lancet JE, Pilon-Thomas S, Dong N, Jain AG, Tan E, Ball S, Tworoger SS, Siegel EM, Whiting J, Mo Q, Cubitt CL, Dukes CW, Hensel JA, Keenan RJ, Hwu P. Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida. JAMA Oncol. 2022 Mar. Pubmedid: 35266953. Pmcid: PMC8914884.
  • Ospina OE, Wilson CM, Soupir AC, Berglund A, Smalley I, Tsai KY, Fridley B. spatialGE: Quantification and visualization of the tumor microenvironment heterogeneity using spatial transcriptomics. Bioinformatics. 2022 Mar. Pubmedid: 35258565.
  • Chiappori AA, Creelan B, Tanvetyanon T, Gray JE, Haura EB, Thapa R, Barlow ML, Chen Z, Chen DT, Beg AA, Boyle TA, Castro J, Morgan L, Morris E, Aregay M, Hurtado FK, Manenti L, Antonia S. Phase I study of taminadenant (PBF509/NIR178), an adenosine 2A receptor antagonist, with or without spartalizumab, in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2022 Mar. Pubmedid: 35254415.
  • Wilson C, Soupir AC, Thapa R, Creed J, Nguyen J, Segura CM, Gerke T, Schildkraut JM, Peres LC, Fridley BL. Tumor immune cell clustering and its association with survival in African American women with ovarian cancer. PLoS Comput Biol. 2022 Mar.18(3):e1009900. Pubmedid: 35235563. Pmcid: PMC8920290.
  • Vinci C, Hemenway M, Baban SS, Yang MJ, Brandon KO, Witkiewitz K, Unrod M, Brandon TH, Wetter DW, Sutton SK. Transition to telehealth: Challenges and benefits of conducting group-based smoking and alcohol treatment virtually. Contemp Clin Trials. 2022 Mar.114:106689. Pubmedid: 35085833. Pmcid: PMC8785408.
  • Giuliano AR, Pilon-Thomas S, Schell MJ, Abrahamsen M, Islam JY, Isaacs-Soriano K, Kennedy K, Dukes CW, Whiting J, Rathwell J, Hensel JA, Mangual LN, Schonbrunn E, Bikowitz M, Grassie D, Yang Y. SARS-CoV-2 Period Seroprevalence and Related Factors, Hillsborough County, Florida, USA, October 2020-March 2021. Emerg Infect Dis. 2022 Mar.28(3):556-563. Pubmedid: 35081021. Pmcid: PMC8888241.
  • Ferrall-Fairbanks MC, Chakiryan N, Chobrutskiy BI, Kim Y, Teer JK, Berglund A, Mulé JJ, Fournier M, Siegel EM, Dhillon J, Falasiri SSA, Arturo JF, Katende EN, Blanck G, Manley BJ, Altrock PM. Quantification of T- and B-cell Immune Receptor Distribution Diversity Characterizes Immune Cell Infiltration and Lymphocyte Heterogeneity in Clear Cell Renal Cell Carcinoma. Cancer Res. 2022 Mar.82(5):929-942. Pubmedid: 35031572. Pmcid: PMC8898280.
  • Samanic CM, Teer JK, Thompson ZJ, Creed JH, Fridley BL, Burt Nabors L, Williams SL, Egan KM. Mitochondrial DNA sequence variation and risk of glioma. Mitochondrion. 2022 Mar.63:32-36. Pubmedid: 35032707. Pmcid: PMC8885975.
  • Mandal G, Biswas S, Anadon CM, Yu X, Gatenbee CD, Prabhakaran S, Payne KK, Chaurio RA, Martin A, Innamarato P, Moran C, Powers JJ, Harro CM, Mine JA, Sprenger KB, Rigolizzo KE, Wang X, Curiel TJ, Rodriguez PC, Anderson ARA, Saglam O, Conejo-Garcia JR. IgA-Dominated Humoral Immune Responses Govern Patients' Outcome in Endometrial Cancer. Cancer Res. 2022 Mar.82(5):859-871. Pubmedid: 34949671. Pmcid: PMC8898267.
  • Brechbuhl HM, Xie M, Kopin EG, Han AL, Vinod-Paul K, Hagen J, Edgerton S, Owens P, Sams S, Elias A, Sartorius CA, Tan AC, Kabos P. Neoadjuvant endocrine therapy expands stromal populations that predict poor prognosis in estrogen receptor-positive breast cancer. Mol Carcinogen. 2022 Mar.61(3):359-371. Pubmedid: 34856027.
  • Simmons VN, Sutton SK, Medina-Ramirez P, Martinez U, Brandon KO, Byrne MM, Meade CD, Meltzer LR, Brandon TH. Self-help smoking cessation intervention for Spanish-speaking Hispanics/Latinxs in the United States: A randomized controlled trial. Cancer. 2022 Mar.128(5):984-994. Pubmedid: 34679188.
  • Walton K, Walker K, Riddle M, Koehn BH, Reff J, Sagatys EM, Linden MA, Pidala J, Kim J, Lee MC, Kiluk JV, Hui JYC, Yun SY, Xing Y, Stefanski H, Lawrence HR, Lawrence NJ, Tolar J, Anasetti C, Blazar BR, Sebti SM, Betts BC. Dual JAK2/Aurora kinase A inhibition prevents human skin graft rejection by allo-inactivation and ILC2-mediated tissue repair. Am J Transplant. 2022 Mar.22(3):717-730. Pubmedid: 34668635. Pmcid: PMC8897228.
  • Tomaszewski MR, Fan S, Garcia A, Qi J, Kim Y, Gatenby RA, Schabath MB, Tap WD, Reinke DK, Makanji RJ, Reed DR, Gillies RJ. AI-Radiomics Can Improve Inclusion Criteria and Clinical Trial Performance. Tomography. 2022 Feb.8(1):341-355. Pubmedid: 35202193. Pmcid: PMC8880510.
  • Chatzkel J, Schell MJ, Chahoud J, Zhang J, Jain R, Swank J, Ludlow S, Lombardi K, Lucas Y, Croft C, Rembisz J, Jameel G, Fishman M. Coordinated Pembrolizumab and High Dose IL-2 (5-in-a-Row Schedule) for Therapy of Metastatic Clear Cell Renal Cancer. Clin Genitourin Cancer. 2022 Feb. Pubmedid: 35249821.
  • Kim J, Lee JH. A novel graphical evaluation of agreement. BMC Med Res Methodol. 2022 Feb.22(1):51. Pubmedid: 35184729. Pmcid: PMC8858529.
  • Obermayer A, Dong L, Hu Q, Golden M, Noble JD, Rodriguez P, Robinson TJ, Teng M, Tan AC, Shaw TI. DRPPM-EASY: A Web-Based Framework for Integrative Analysis of Multi-Omics Cancer Datasets. Biology (Basel). 2022 Feb.11(2). Pubmedid: 35205126. Pmcid: PMC8869715.
  • Law V, Chen Z, Vena F, Smalley I, Macaulay R, Evernden BR, Tran N, Pina Y, Puskas J, Caceres G, Bayle S, Johnson J, Liu JKC, Etame A, Vogelbaum M, Rodriguez P, Duckett D, Czerniecki B, Chen A, Smalley KSM, Forsyth PA. A preclinical model of patient-derived cerebrospinal fluid circulating tumor cells for experimental therapeutics in leptomeningeal disease from melanoma. Neurooncol. 2022 Feb. Pubmedid: 35213727.
  • Bag A, Schultz A, Bhimani S, Stringfield O, Dominguez W, Mo Q, Cen L, Adeegbe D. Coupling the immunomodulatory properties of the HDAC6 inhibitor ACY241 with Oxaliplatin promotes robust anti-tumor response in non-small cell lung cancer. Oncoimmunology. 2022 Feb.11(1):2042065. Pubmedid: 35223194. Pmcid: PMC8865306.
  • Coghill AE, Kim Y, Hodge JM, Bender N, Smith-Warner SA, Teras LR, Grimsrud TK, Waterboer T, Egan KM. Prospective investigation of herpesvirus infection and risk of glioma. Int J Cancer. 2022 Feb. Pubmedid: 35225352.
  • Saglam O, Cao B, Wang X, Toruner GA, Conejo-Garcia JR. Expression of epigenetic pathway related genes in association with PD-L1, ER/PgR and MLH1 in endometrial carcinoma. PLoS One. 2022 Feb.17(2):e0264014. Pubmedid: 35226658. Pmcid: PMC8884513.
  • Shabani S, Turner K, Nichols AC, Wang X, Patel KB. A Review of Health Care Disparities in Head and Neck Squamous Cell Carcinomas. J Health Care Poor Underserved. 2022 Feb.33(1):478-491. Pubmedid: 35153235.
  • Wei G, Teng M, Rosa M, Wang X. Unique ER PR expression pattern in breast cancers with CHEK2 mutation: a hormone receptor and HER2 analysis based on germline cancer predisposition genes. Breast Cancer Res. 2022 Feb.24(1):11. Pubmedid: 35135604. Pmcid: PMC8822747.
  • Napoli M, Wu SJ, Gore BL, Abbas H, Lee K, Checker R, Dhar S, Rajapakshe K, Tan AC, Lee MG, Coarfa C, Flores ER. ΔNp63 regulates a common landscape of enhancer associated genes in non-small cell lung cancer. Nat Commun. 2022 Feb.13(1):614. Pubmedid: 35105868. Pmcid: PMC8807845.
  • Carr MJ, Sun J, DePalo D, Rothermel LD, Song Y, Straker RJ, Baecher K, Louie RJ, Stahlie EHA, Wright GP, Naqvi SMH, Kim Y, Sarnaik AA, Karakousis GC, Lowe MC, Delman KA, van Akkooi ACJ, Ollila DW, Collichio F, Zager JS. ASO Visual Abstract: Talimogene Laherparepvec (T-VEC) for Treatment of Advanced Locoregional Melanoma after Failure of Immunotherapy: An International Multi-institutional Experience. Ann Surg Oncol. 2022 Feb.29(2):804-805. Pubmedid: 34817772.
  • Carr MJ, Sun J, DePalo D, Rothermel LD, Song Y, Straker RJ, Baecher K, Louie RJ, Stahlie EHA, Wright GP, Naqvi SMH, Kim Y, Sarnaik AA, Karakousis GC, Lowe MC, Delman KA, van Akkooi ACJ, Ollila DW, Collichio F, Zager JS. Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience. Ann Surg Oncol. 2022 Feb.29(2):791-801. Pubmedid: 34648098.
  • McLeod KL, Skinner AM, Beaupin LK, Vadaparampil ST, Fridley BL, Reed DR. Clinical Trial Availability by Location for 1000 Simulated AYA Patients. J Adolesc Young Adult Oncol. 2022 Feb.11(1):95-103. Pubmedid: 33983850. Pmcid: PMC8864422.
  • Patel SY, Trona N, Alford B, Laborde JM, Kim Y, Li R, Manley BJ, Gilbert SM, Sexton WJ, Spiess PE, Poch MA. Preoperative immunonutrition and carbohydrate loading associated with improved bowel function after radical cystectomy. Nutr Clin Pract. 2022 Feb.37(1):176-182. Pubmedid: 33900647.
  • Buro AW, Baskin M, Miller D, Ward T, West DS, Gore LR, Gwede CK, Epel E, Carson TL. Rationale and study protocol for a randomized controlled trial to determine the effectiveness of a culturally relevant, stress management enhanced behavioral weight loss intervention on weight loss outcomes of black women. BMC Public Health. 2022 Jan.22(1):193. Pubmedid: 35090433. Pmcid: PMC8795937.
  • Buras AL, Wang T, Whiting J, Townsend MK, Fridley BL, Tworoger SS. Prospective Analyses of Sedentary Behavior in Relation to Risk of Ovarian Cancer. Am J Epidemiol. 2022 Jan. Pubmedid: 35094053.
  • Tarhini AA, Lee SJ, Tan AC, El Naqa IM, Stephen Hodi F, Butterfield LH, LaFramboise WA, Storkus WJ, Karunamurthy AD, Conejo-Garcia JR, Hwu P, Streicher H, Sondak VK, Kirkwood JM. Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary. J Immunother Cancer. 2022 Jan.10(1). Pubmedid: 35074904. Pmcid: PMC8788316.
  • Amorrortu RP, Zhao Y, Fenske NA, Cherpelis BS, Messina JL, Giuliano AR, Sondak VK, Schell MJ, Mckay-Chopin S, Gheit T, Waterboer T, Tommasino M, Rollison DE. Natural history of incident and persistent cutaneous human papillomavirus and human polyomavirus infections. J Infect Dis. 2022 Jan. Pubmedid: 35022780.
  • Chaurio RA, Anadon CM, Lee Costich T, Payne KK, Biswas S, Harro CM, Moran C, Ortiz AC, Cortina C, Rigolizzo KE, Sprenger KB, Mine JA, Innamarato P, Mandal G, Powers JJ, Martin A, Wang Z, Mehta S, Perez BA, Li R, Robinson J, Kroeger JL, Curiel TJ, Yu X, Rodriguez PC, Conejo-Garcia JR. TGF-β-mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures. Immunity. 2022 Jan.55(1):115-128.e9. Pubmedid: 35021053. Pmcid: PMC8852221.
  • Li K, Yao S, Zhang Z, Cao B, Wilson CM, Kalos D, Kuan PF, Zhu R, Wang X. Efficient gradient boosting for prognostic biomarker discovery. Bioinformatics. 2022 Jan. Pubmedid: 34978570.
  • Nakamura K, Reid BM, Chen A, Chen Z, Goode EL, Permuth JB, Teer JK, Tyrer J, Yu X, Kanetsky PA, Pharoah PD, Gayther SA, Sellers TA, Lawrenson K, Karreth FA. Functional analysis of the 1p34.3 risk locus implicates GNL2 in high-grade serous ovarian cancer. Am J Hum Genet. 2022 Jan.109(1):116-135. Pubmedid: 34965383. Pmcid: PMC8764204.
  • Lazaryan A, Lee SJ, Arora M, Kim J, Betts BC, Khimani F, Nishihori T, Bejanyan N, Liu H, Kharfan-Dabaja MA, Locke FL, Gonzalez R, Jain MD, Davila ML, Perez LE, Mishra A, Perez Perez A, Balke K, Ayala E, Ochoa L, Castaneda Puglianini O, Faramand RG, Alsina M, Elmariah H, Nieder M, Fernandez H, Anasetti C, Pidala J. A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease. Blood Adv. 2022 Jan.6(1):259-269. Pubmedid: 34649279. Pmcid: PMC8753213.
  • Malachowski SJ, Moy A, Messina J, Chen YA, Sun J, Sokol L, Seminario-Vidal L. Mapping cutaneous T-cell lymphoma in the state of Florida: A retrospective exploratory spatial analysis of incidence patterns. J Am Acad Dermatol. 2022 Jan.86(1):186-188. Pubmedid: 33476732.
  • Berglund A, Matta J, Encarnación-Medina J, Ortiz-Sanchéz C, Dutil J, Linares R, Marcial J, Abreu-Takemura C, Moreno N, Putney R, Chakrabarti R, Lin HY, Yamoah K, Osterman CD, Wang L, Dhillon J, Kim Y, Kim SJ, Ruiz-Deya G, Park JY. Dysregulation of DNA Methylation and Epigenetic Clocks in Prostate Cancer among Puerto Rican Men. Biomolecules. 2021 Dec.12(1). Pubmedid: 35053153. Pmcid: PMC8773891.
  • Wu Q, Berglund AE, MacAulay RJ, Etame AB. A Novel Role of BIRC3 in Stemness Reprogramming of Glioblastoma. Int J Mol Sci. 2021 Dec.23(1). Pubmedid: 35008722. Pmcid: PMC8745052.
  • Jones SR, Vidrine DJ, Wetter DW, Shih YT, Sutton SK, Ramondetta LM, Elting LS, Walker JL, Smith KM, Frank-Pearce SG, Li Y, Simmons VN, Vidrine JI. Evaluation of the Efficacy of a Smoking Cessation Intervention for Cervical Cancer Survivors and Women With High-Grade Cervical Dysplasia: Protocol for a Randomized Controlled Trial. JMIR Res Protoc. 2021 Dec.10(12):e34502. Pubmedid: 34967755. Pmcid: PMC8765796.
  • Mo Q, Wan L, Schell MJ, Jim H, Tworoger SS, Peng G. Integrative Analysis Identifies Multi-Omics Signatures That Drive Molecular Classification of Uveal Melanoma. Cancers (Basel). 2021 Dec.13(24). Pubmedid: 34944787. Pmcid: PMC8699355.
  • Chai AWY, Tan AC, Cheong SC. Uncovering drug repurposing candidates for head and neck cancers: insights from systematic pharmacogenomics data analysis. Sci Rep. 2021 Dec.11(1):23933. Pubmedid: 34907286. Pmcid: PMC8671460.
  • Kwak YD, Shaw TI, Downing SM, Tewari A, Jin H, Li Y, Dumitrache LC, Katyal S, Khodakhah K, Russell HR, McKinnon PJ. Chromatin architecture at susceptible gene loci in cerebellar Purkinje cells characterizes DNA damage-induced neurodegeneration. Sci Adv. 2021 Dec.7(51):eabg6363. Pubmedid: 34910524.
  • Siegel EM, Ajidahun A, Berglund A, Guerrero W, Eschrich S, Putney RM, Magliocco A, Riggs B, Winter K, Simko JP, Ajani JA, Guha C, Okawara GS, Abdalla I, Becker MJ, Pizzolato JF, Crane CH, Brown KD, Shibata D. Genome-wide host methylation profiling of anal and cervical carcinoma. PLoS One. 2021 Dec.16(12):e0260857. Pubmedid: 34882728. Pmcid: PMC8659695.
  • Mostofa A, Distler A, Meads MB, Sahakian E, Powers JJ, Achille A, Noyes D, Wright G, Fang B, Izumi V, Koomen J, Rampakrishnan R, Nguyen TP, De Avila G, Silva AS, Sudalagunta P, Canevarolo RR, Siqueira Silva MDC, Alugubelli RR, Dai HA, Kulkarni A, Dalton WS, Hampton OA, Welsh EA, Teer JK, Tungesvik A, Wright KL, Pinilla-Ibarz J, Sotomayor EM, Shain KH, Brayer J. Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma. JCI Insight. 2021 Dec.6(24). Pubmedid: 34793338. Pmcid: PMC8783683.
  • Gajzer D, Logothetis CN, Sallman DA, Calon G, Babu A, Chan O, Vincelette ND, Volpe VO, Al Ali NH, Basra P, Talati C, Kuykendall AT, Mo Q, Padron E, Sweet K, Komrokji RS, Lancet JE, Yun S, Zhang L. MYC overexpression is associated with an early disease progression from MDS to AML. Leuk Res. 2021 Dec.111:106733. Pubmedid: 34749168. Pmcid: PMC8643343.
  • Aditi, Downing SM, Schreiner PA, Kwak YD, Li Y, Shaw TI, Russell HR, McKinnon PJ. Genome instability independent of type I interferon signaling drives neuropathology caused by impaired ribonucleotide excision repair. Neuron. 2021 Dec.109(24):3962-3979.e6. Pubmedid: 34655526. Pmcid: PMC8686690.
  • Teng M, Du D, Chen D, Irizarry RA. Characterizing batch effects and binding site-specific variability in ChIP-seq data. NAR Genom Bioinform. 2021 Dec.3(4):lqab098. Pubmedid: 34661103. Pmcid: PMC8515842.
  • Samanic CM, Teer JK, Thompson ZJ, Creed JH, Mokhtari S, Fridley BL, Nabors LB, Williams SL, Egan KM. Mitochondrial DNA sequence variation and risk of meningioma. J Neurooncol. 2021 Dec.155(3):319-324. Pubmedid: 34669147.
  • Huang BJ, Smith J, Wang J, Taghizadeh K, Leonti AR, Ries RE, Liu Y, Kolekar P, Tarlock K, Gerbing RB, Crowgey E, Furlan SN, Shaw TI, Hagiwara K, Wei L, Cooper T, Gamis AS, Aplenc R, Kolb EA, Farrar JE, Triche TJ, Alonzo T, Ma X, Meshinchi S. CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes. Blood Adv. 2021 Dec.5(23):4963-4968. Pubmedid: 34547772.
  • Mishra A, Pidala J, Thapa R, Betts BC, Fernandez H, Locke FL, Nishihori T, Perez L, Wang X, Anasetti C, Jim H. Objective and subjective physical function in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2021 Dec.56(12):2897-2903. Pubmedid: 34381169.
  • Figura NB, Robinson TJ, Sim AJ, Wang X, Cao B, Chavez JC, Shah BD, Khimani F, Lazaryan A, Davila M, Bachmeier C, Nishihori T, Liu HD, Kim S, Locke FL, Jain MD. Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy. Int J Radiat Oncol Biol Phys. 2021 Dec.111(5):1145-1154. Pubmedid: 34242714.
  • Wang Z, Guo R, Trudeau SJ, Wolinsky E, Ast T, Liang JH, Jiang C, Ma Y, Teng M, Mootha V, Gewurz B. CYB561A3 is the key lysosomal iron reductase required for Burkitt B-cell growth and survival. Blood. 2021 Dec.138(22):2216-2230. Pubmedid: 34232987. Pmcid: PMC8641094.
  • Jain RK, Skelton Iv WP, Pond GR, Naqvi M, Kim Y, Curran C, Freeman D, Nuzzo PV, Alaiwi SA, Nassar AH, Jain RK, Sonpavde G. Angiotensin Blockade Modulates the Activity of PD1/L1 Inhibitors in Metastatic Urothelial Carcinoma. Clin Genitourin Cancer. 2021 Dec.19(6):540-546. Pubmedid: 34011489. Pmcid: PMC8526625.
  • Shi LL, McMullen C, Vorwald K, Nichols AC, MacNeil SD, Wadsworth JT, Chung CH, Wang X, Patel KB. Survival outcomes of patients with subglottic squamous cell carcinoma : a study of the National Cancer Database. Eur Arch Otorhinolaryngol. 2021 Dec.278(12):4923-4932. Pubmedid: 33646344.
  • Hunter AM, Newman H, DeZern AE, Steensma DP, Niyongere S, Roboz GJ, Mo Q, Chan O, Gerds A, Sallman DA, Dominguez-Viqueira W, Letson C, Balasis ME, Ball M, Kruer T, Zhang H, Lancet JE, List AF, Sekeres MA, Komrokji RS, Padron E. Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia. Clin Cancer Res. 2021 Nov.27(22):6095-6105. Pubmedid: 34253584. Pmcid: PMC8595542.
  • Huang J, Soupir AC, Schlick BD, Teng M, Sahin IH, Permuth JB, Siegel EM, Manley BJ, Pellini B, Wang L. Cancer Detection and Classification by CpG Island Hypermethylation Signatures in Plasma Cell-Free DNA. Cancers (Basel). 2021 Nov.13(22). Pubmedid: 34830765. Pmcid: PMC8616264.
  • Saeed-Vafa D, Marchion DC, McCarthy SM, Hakam A, Lopez A, Wenham RM, Apte SM, Chen DT, Magliocco AM, Lancaster JM, Reid BM, Permuth JB. Utilizing digital pathology to quantify stromal caveolin-1 expression in malignant and benign ovarian tumors: Associations with clinicopathological parameters and clinical outcomes. PLoS One. 2021 Nov.16(11):e0256615. Pubmedid: 34813586. Pmcid: PMC8610269.
  • Rollison DE, Messina JL, Cherpelis BS, Fenske NA, Schell MJ, Adeegbe DO, Zhao Y, Amorrortu RP, Akuffo AA, Hesterberg RS, Epling-Burnette PK. Circulating Immunosuppressive Regulatory T Cells Predict Risk of Incident Cutaneous Squamous Cell Carcinoma. Front Med (Lausanne). 2021 Nov.8:735585. Pubmedid: 34796183. Pmcid: PMC8593034.
  • Vidrine DJ, Bui TC, Businelle MS, Shih YT, Sutton SK, Shahani L, Hoover DS, Bowles K, Vidrine JI. Evaluating the Efficacy of Automated Smoking Treatment for People With HIV: Protocol for a Randomized Controlled Trial. JMIR Res Protoc. 2021 Nov.10(11):e33183. Pubmedid: 34787590. Pmcid: PMC8663670.
  • Wen J, Rusch M, Brady SW, Shao Y, Edmonson MN, Shaw TI, Powers BB, Tian L, Easton J, Mullighan CG, Gruber T, Ellison D, Zhang J. The landscape of coding RNA editing events in pediatric cancer. BMC Cancer. 2021 Nov.21(1):1233. Pubmedid: 34789196. Pmcid: PMC8597231.
  • Creed JH, Wilson CM, Soupir AC, Colin-Leitzinger CM, Kimmel GJ, Ospina OE, Chakiryan NH, Markowitz J, Peres LC, Coghill A, Fridley BL. spatialTIME and iTIME: R package and Shiny application for visualization and analysis of immunofluorescence data. Bioinformatics. 2021 Nov. Pubmedid: 34734969. Pmcid: PMC8652029.
  • Alfonso JCL, Grass GD, Welsh E, Ahmed KA, Teer JK, Pilon-Thomas S, Harrison LB, Cleveland JL, Mulé JJ, Eschrich SA, Torres-Roca JF, Enderling H. Tumor-immune ecosystem dynamics define an individual Radiation Immune Score to predict pan-cancer radiocurability. Neoplasia. 2021 Nov.23(11):1110-1122. Pubmedid: 34619428. Pmcid: PMC8502777.
  • Khimani F, Ranspach P, Elmariah H, Kim J, Whiting J, Nishihori T, Locke FL, Perez Perez A, Dean E, Mishra A, Perez L, Lazaryan A, Jain MD, Nieder M, Liu H, Faramand R, Hansen D, Alsina M, Ochoa L, Davila M, Anasetti C, Pidala J, Bejanyan N. Increased Infections and Delayed CD4+ T Cell but Faster B Cell Immune Reconstitution after Post-Transplantation Cyclophosphamide Compared to Conventional GVHD Prophylaxis in Allogeneic Transplantation. Transplant Cell Ther. 2021 Nov.27(11):940-948. Pubmedid: 34329754.
  • El-Kenawi A, Dominguez-Viqueira W, Liu M, Awasthi S, Abraham-Miranda J, Keske A, Steiner KK, Noel L, Serna AN, Dhillon J, Gillies RJ, Yu X, Koomen JM, Yamoah K, Gatenby RA, Ruffell B. Macrophage-Derived Cholesterol Contributes to Therapeutic Resistance in Prostate Cancer. Cancer Res. 2021 Nov.81(21):5477-5490. Pubmedid: 34301759. Pmcid: PMC8563406.
  • Thota R, Yang M, Pflieger L, Schell MJ, Rajan M, Davis TB, Wang H, Presson A, Pledger WJ, Yeatman TJ. APC and TP53 Mutations Predict Cetuximab Sensitivity across Consensus Molecular Subtypes. Cancers (Basel). 2021 Oct.13(21). Pubmedid: 34771559. Pmcid: PMC8582550.
  • Vanderwall D, Suresh P, Fu Y, Cho JH, Shaw TI, Mishra A, High AA, Peng J, Li Y. JUMPn: A Streamlined Application for Protein Co-Expression Clustering and Network Analysis in Proteomics. J Vis Exp. 2021 Oct.(176). Pubmedid: 34747401.
  • Nassar KW, Hintzsche JD, Bagby SM, Espinoza V, Langouët-Astrié C, Amato CM, Chimed TS, Fujita M, Robinson W, Tan AC, Schweppe RE. Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma. Mol Cancer Ther. 2021 Oct.20(10):2049-2060. Pubmedid: 34376578.
  • Reid S, Haddad D, Tezak A, Weidner A, Wang X, Mautz B, Moore J, Cadiz S, Zhu Y, Zheng W, Mayer IA, Shu XO, Pal T. Impact of molecular subtype and race on HR+, HER2- breast cancer survival. Breast Cancer Res Treat. 2021 Oct.189(3):845-852. Pubmedid: 34331630. Pmcid: PMC8511072.
  • Ahmed KA, Kim Y, Arrington JA, Kim S, DeJesus M, Soyano AE, Armaghani AJ, Costa RLB, Khong HT, Loftus LS, Rosa M, Caudell JJ, Diaz R, Robinson TJ, Etame AB, Tran ND, Sahebjam S, Soliman HH, Czerniecki BJ, Forsyth PA, Yu HM, Han HS. Nivolumab and Stereotactic Radiosurgery for Patients With Breast Cancer Brain Metastases: A Nonrandomized, Open-Label Phase 1b Study. Adv Radiat Oncol. 2021 Sep.6(6):100798. Pubmedid: 34934864. Pmcid: PMC8655428.
  • Lee K, Lockhart JH, Xie M, Chaudhary R, Slebos RJC, Flores ER, Chung CH, Tan AC. Deep Learning of Histopathology Images at the Single Cell Level. Front Artif Intell. 2021 Sep.4:754641. Pubmedid: 34568816. Pmcid: PMC8461055.
  • Xiong Z, Jeon M, Allaway RJ, Kang J, Park D, Lee J, Jeon H, Ko M, Jiang H, Zheng M, Tan AC, Guo X, Dang KK, Tropsha A, Hecht C, Das TK, Carlson HA, Abagyan R, Guinney J, Schlessinger A, Cagan R. Crowdsourced identification of multi-target kinase inhibitors for RET- and TAU- based disease: The Multi-Targeting Drug DREAM Challenge. PLoS Comput Biol. 2021 Sep.17(9):e1009302. Pubmedid: 34520464. Pmcid: PMC8483411.
  • de la Iglesia JV, Slebos RJC, Martin-Gomez L, Wang X, Teer JK, Tan AC, Gerke TA, Aden-Buie G, van Veen T, Masannat J, Chaudhary R, Song F, Fournier M, Siegel EM, Schabath MB, Wadsworth JT, Caudell J, Harrison L, Wenig BM, Conejo-Garcia J, Hernandez-Prera JC, Chung CH. Correction: Effects of Tobacco Smoking On the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2021 Sep.27(17):4941. Pubmedid: 34470812.
  • Scott JG, Sedor G, Ellsworth P, Scarborough JA, Ahmed KA, Oliver DE, Eschrich SA, Kattan MW, Torres-Roca JF. Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysis. Lancet Oncol. 2021 Sep.22(9):1221-1229. Pubmedid: 34363761.
  • Cheng N, Mo Q, Donelson J, Wang L, Breton G, Rodney GG, Wang J, Hirschi KD, Wehrens XHT, Nakata PA. Crucial Role of Mammalian Glutaredoxin 3 in Cardiac Energy Metabolism in Diet-induced Obese Mice Revealed by Transcriptome Analysis. Int J Biol Sci. 2021 Jul.17(11):2871-2883. Pubmedid: 34345213. Pmcid: PMC8326124.
  • Rollison DE, Amorrortu RP, Zhao Y, Messina JL, Schell MJ, Fenske NA, Cherpelis BS, Giuliano AR, Sondak VK, Pawlita M, McKay-Chopin S, Gheit T, Waterboer T, Tommasino M. Cutaneous Human Papillomaviruses and the Risk of Keratinocyte Carcinomas. Cancer Res. 2021 Sep.81(17):4628-4638. Pubmedid: 34266893. Pmcid: PMC8416805.
  • Amorrortu RP, Zhao Y, Messina JL, Schell MJ, Fenske NA, Cherpelis BS, Sondak VK, Giuliano AR, Pawlita M, McKay-Chopin S, Gheit T, Waterboer T, Tommasino M, Rollison DE. Association between Human Polyomaviruses and Keratinocyte Carcinomas: A Prospective Cohort Study. Cancer Epidemiol Biomarkers Prev. 2021 Sep.30(9):1761-1764. Pubmedid: 34187857. Pmcid: PMC8419098.
  • Naffouje S, Sabesan A, Powers BD, Dessureault S, Sanchez J, Schell M, Imanirad I, Sahin I, Xie H, Felder S. Patient Risk Subgroups Predict Benefit of Adjuvant Chemotherapy in Stage II Rectal Cancer Patients Following Neoadjuvant Chemoradiation and Total Mesorectal Excision. Clin Colorectal Cancer. 2021 Sep.20(3):e155-e164. Pubmedid: 33775560.
  • Tunali I, Tan Y, Gray JE, Katsoulakis E, Eschrich SA, Saller J, Aerts HJWL, Boyle T, Qi J, Guvenis A, Gillies RJ, Schabath MB. Hypoxia-Related Radiomics and Immunotherapy Response: A Multicohort Study of Non-Small Cell Lung Cancer. JNCI Cancer Spectr. 2021 Aug.5(4). Pubmedid: 34409252. Pmcid: PMC8363765.
  • Creelan BC, Wang C, Teer JK, Toloza EM, Yao J, Kim S, Landin AM, Mullinax JE, Saller JJ, Saltos AN, Noyes DR, Montoya LB, Curry W, Pilon-Thomas SA, Chiappori AA, Tanvetyanon T, Kaye FJ, Thompson ZJ, Yoder SJ, Fang B, Koomen JM, Sarnaik AA, Chen DT, Conejo-Garcia JR, Haura EB, Antonia SJ. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat Med. 2021 Aug.27(8):1410-1418. Pubmedid: 34385708. Pmcid: PMC8509078.
  • Padmanabhan J, Saha B, Powell C, Mo Q, Perez BA, Chellappan S. Inhibitors Targeting CDK9 Show High Efficacy against Osimertinib and AMG510 Resistant Lung Adenocarcinoma Cells. Cancers (Basel). 2021 Aug.13(15). Pubmedid: 34359807. Pmcid: PMC8345430.
  • Wu Q, Berglund AE, Etame AB. The Impact of Epigenetic Modifications on Adaptive Resistance Evolution in Glioblastoma. Int J Mol Sci. 2021 Aug.22(15). Pubmedid: 34361090. Pmcid: PMC8347012.
  • Siegel EL, Whiting J, Kim Y, Sun W, Laronga C, Lee MC. Effect of surgical complications on outcomes in breast cancer patients treated with mastectomy and immediate reconstruction. Breast Cancer Res Treat. 2021 Aug.188(3):641-648. Pubmedid: 33939063.
  • Smalley KSM, Teer JK, Chen YA, Wu JY, Yao J, Koomen JM, Chen WS, Rodriguez-Waitkus P, Karreth FA, Messina JL. A Mutational Survey of Acral Nevi. JAMA Dermatol. 2021 Jul.157(7):831-835. Pubmedid: 33978681. Pmcid: PMC8117064.
  • Permuth JB, Vyas S, Li J, Chen DT, Jeong D, Choi JW. Comparison of Radiomic Features in a Diverse Cohort of Patients With Pancreatic Ductal Adenocarcinomas. Front Oncol. 2021 Jul.11:712950. Pubmedid: 34367997. Pmcid: PMC8339963.
  • Wu F, Nie S, Yao Y, Huo T, Li X, Wu X, Zhao J, Lin YL, Zhang Y, Mo Q, Song Y. Small-molecule inhibitor of AF9/ENL-DOT1L/AF4/AFF4 interactions suppresses malignant gene expression and tumor growth. Theranostics. 2021 Jul.11(17):8172-8184. Pubmedid: 34373735. Pmcid: PMC8344022.
  • Chakiryan NH, Kimmel GJ, Kim Y, Johnson JO, Clark N, Hajiran A, Chang A, Aydin AM, Zemp L, Katende E, Chahoud J, Ferrall-Fairbanks MC, Spiess PE, Francis N, Fournier M, Dhillon J, Park JY, Wang L, Mulé JJ, Altrock PM, Manley BJ. Geospatial Cellular Distribution of Cancer-Associated Fibroblasts Significantly Impacts Clinical Outcomes in Metastatic Clear Cell Renal Cell Carcinoma. Cancers (Basel). 2021 Jul.13(15). Pubmedid: 34359645. Pmcid: PMC8345222.
  • Dash S, Yoder S, Mesa T, Smith A, Cen L, Eschrich S, Armaiz-Pena GN, Monteiro ANA. Effects of long-term norepinephrine treatment on normal immortalized ovarian and fallopian tube cells. Sci Rep. 2021 Jul.11(1):14334. Pubmedid: 34253763. Pmcid: PMC8275603.
  • Ganguly S, Finkelstein D, Shaw TI, Michalek RD, Zorn KM, Ekins S, Yasuda K, Fukuda Y, Schuetz JD, Mukherjee K, Schuetz EG. Metabolomic and transcriptomic analysis reveals endogenous substrates and metabolic adaptation in rats lacking Abcg2 and Abcb1a transporters. PLoS One. 2021 Jul.16(7):e0253852. Pubmedid: 34255797. Pmcid: PMC8277073.
  • Perez L, Fernandez H, Kharfan-Dabaja M, Khimani F, Betts B, Mishra A, Ayala E, Locke FL, Ochoa-Bayona L, Nieder M, Pidala J, Achille A, Powers J, Sahakian E, Thapa R, Wang X, Anasetti C. A phase 2 trial of the histone deacetylase inhibitor panobinostat for graft-versus-host disease prevention. Blood Adv. 2021 Jul.5(13):2740-2750. Pubmedid: 34242388. Pmcid: PMC8288668.
  • Chen DT, Chan W, Thompson ZJ, Thapa R, Beg AA, Saltos AN, Chiappori AA, Gray JE, Haura EB, Rose TA, Creelan B. Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer. PLoS One. 2021 Jul.16(7):e0252041. Pubmedid: 34197475. Pmcid: PMC8248740.
  • Martinez U, Simmons VN, Sutton SK, Drobes DJ, Meltzer LR, Brandon KO, Byrne MM, Harrell PT, Eissenberg T, Bullen CR, Brandon TH. Targeted smoking cessation for dual users of combustible and electronic cigarettes: a randomised controlled trial. Lancet Public Health. 2021 Jul.6(7):e500-e509. Pubmedid: 34175001. Pmcid: PMC8281505.
  • Smalley I, Chen Z, Phadke MS, Li J, Yu X, Wyatt C, Evernden B, Messina JL, Sarnaik A, Sondak VK, Zhang C, Law V, Tran N, Etame A, Macaulay RJB, Eroglu Z, Forsyth PA, Rodriguez PC, Chen YA, Smalley KSM. Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases. Clin Cancer Res. 2021 Jul.27(14):4109-4125. Pubmedid: 34035069. Pmcid: PMC8282775.
  • Broman KK, Hughes T, Dossett L, Sun J, Kirichenko D, Carr MJ, Sharma A, Bartlett EK, Nijhuis AAG, Thompson JF, Hieken TJ, Kottschade L, Downs J, Gyorki DE, Stahlie E, van Akkooi A, Ollila DW, Frank J, Song Y, Karakousis G, Moncrieff M, Nobes J, Vetto J, Han D, Farma JM, Deneve JL, Fleming MD, Perez MC, Lowe MC, Olofsson Bagge R, Mattsson J, Lee AY, Berman RS, Chai H, Kroon HM, Teras J, Teras RM, Farrow NE, Beasley G, Hui JYC, Been L, Kruijff S, Kim Y, Naqvi SMH, Sarnaik AA, Sondak VK, Zager JS. Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-2). Cancer. 2021 Jul.127(13):2251-2261. Pubmedid: 33826754. Pmcid: PMC8764513.
  • Dong N, Castillo Tokumori F, Isenalumhe L, Zhang Y, Tandon A, Knepper TC, Mo Q, Shao H, Zhang L, Sokol L. Large granular lymphocytic leukemia - A retrospective study of 319 cases. Am J Hematol. 2021 Jul.96(7):772-780. Pubmedid: 33819354.
  • Yaghjyan L, Mai V, Wang X, Ukhanova M, Tagliamonte M, Martinez YC, Rich SN, Egan KM. Gut microbiome, body weight, and mammographic breast density in healthy postmenopausal women. Cancer Causes Control. 2021 Jul.32(7):681-692. Pubmedid: 33772705.
  • Elmariah H, Naqvi SMH, Kim J, Nishihori T, Mishra A, Perez L, Faramand R, Lazaryan A, Liu HD, Khimani F, Nieder M, Anasetti C, Pidala J, Bejanyan N. Impact of infused CD34+ stem cell dosing for allogeneic peripheral blood stem cell transplantation with post-transplant cyclophosphamide. Bone Marrow Transplant. 2021 Jul.56(7):1683-1690. Pubmedid: 33658647.
  • Pollyea DA, Kim HM, Stevens BM, Lee FF, Harris C, Hedin BR, Knapp JR, O'Connor BP, Jordan CT, Pietras EM, Tan AC, Alper S. MDS-associated SF3B1 mutations enhance proinflammatory gene expression in patient blast cells. J Leukoc Biol. 2021 Jul.110(1):197-205. Pubmedid: 33155727. Pmcid: PMC8612809.
  • Li R, Berglund A, Zemp L, Dhillon J, Putney R, Kim Y, Jain RK, Grass GD, Conejo-Garcia J, Mulé JJ. The 12-CK Score: Global Measurement of Tertiary Lymphoid Structures. Front Immunol. 2021 Jun.12:694079. Pubmedid: 34267760. Pmcid: PMC8276102.
  • Lacson JCA, Doyle SH, Qian L, Del Rio J, Forgas SM, Valavanis S, Carvajal R, Gonzalez-Calderon G, Kim Y, Roetzheim RG, Sutton SK, Vadaparampil ST, Kanetsky PA. A Randomized Trial of Precision Prevention Materials to Improve Primary and Secondary Melanoma Prevention Activities among Individuals with Limited Melanoma Risk Phenotypes. Cancers (Basel). 2021 Jun.13(13). Pubmedid: 34201795. Pmcid: PMC8267659.
  • Wilson CM, Ospina OE, Townsend MK, Nguyen J, Moran Segura C, Schildkraut JM, Tworoger SS, Peres LC, Fridley BL. Challenges and Opportunities in the Statistical Analysis of Multiplex Immunofluorescence Data. Cancers (Basel). 2021 Jun.13(12). Pubmedid: 34204319. Pmcid: PMC8233801.
  • Gordian E, Welsh EA, Gimbrone N, Siegel EM, Shibata D, Creelan BC, Cress WD, Eschrich SA, Haura EB, Muñoz-Antonia T. Correction: Transforming growth factor β-induced epithelial-to-mesenchymal signature predicts metastasis-free survival in non-small cell lung cancer. Oncotarget. 2021 Jun.12(13):1325. Pubmedid: 34194632. Pmcid: PMC8238243.
  • Reid BM, Vyas S, Chen Z, Chen A, Kanetsky PA, Permuth JB, Sellers TA, Saglam O. Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma. BMC Cancer. 2021 Jun.21(1):714. Pubmedid: 34140011. Pmcid: PMC8212453.
  • Wilson CM, Li K, Sun Q, Kuan PF, Wang X. Fenchel duality of Cox partial likelihood with an application in survival kernel learning. Artif Intell Med. 2021 Jun.116:102077. Pubmedid: 34020756. Pmcid: PMC8159024.
  • Koomen DC, Meads MB, Magaletti DM, Guingab-Cagmat JD, Oliveira PS, Fang B, Liu M, Welsh EA, Meke LE, Jiang Z, Hampton OA, Tungesvik A, De Avila G, Alugubelli RR, Nishihori T, Silva AS, Eschrich SA, Garrett TJ, Koomen JM, Shain KH. Metabolic Changes Are Associated with Melphalan Resistance in Multiple Myeloma. J Proteome Res. 2021 Jun.20(6):3134-3149. Pubmedid: 34014671.
  • de Mingo Pulido Á, Hänggi K, Celias DP, Gardner A, Li J, Batista-Bittencourt B, Mohamed E, Trillo-Tinoco J, Osunmakinde O, Peña R, Onimus A, Kaisho T, Kaufmann J, McEachern K, Soliman H, Luca VC, Rodriguez PC, Yu X, Ruffell B. The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake. Immunity. 2021 Jun.54(6):1154-1167.e7. Pubmedid: 33979578. Pmcid: PMC8192496.
  • Schubert L, Le AT, Estrada-Bernal A, Doak AE, Yoo M, Ferrara SE, Goodspeed A, Kinose F, Rix U, Tan AC, Doebele RC. Novel Human-Derived RET Fusion NSCLC Cell Lines Have Heterogeneous Responses to RET Inhibitors and Differential Regulation of Downstream Signaling. Mol Pharmacol. 2021 Jun.99(6):435-447. Pubmedid: 33795352.
  • Mallen A, Todd S, Robertson SE, Kim J, Sehovic M, Wenham RM, Extermann M, Chon HS. Impact of age, comorbidity, and treatment characteristics on survival in older women with advanced high grade epithelial ovarian cancer. Gynecol Oncol. 2021 Jun.161(3):693-699. Pubmedid: 33812698.
  • Haydar D, Houke H, Chiang J, Yi Z, Odé Z, Caldwell K, Zhu X, Mercer KS, Stripay JL, Shaw TI, Vogel P, DeRenzo C, Baker SJ, Roussel MF, Gottschalk S, Krenciute G. Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery. Neurooncol. 2021 Jun.23(6):999-1011. Pubmedid: 33320196. Pmcid: PMC8168826.
  • Sallman DA, DeZern AE, Garcia-Manero G, Steensma DP, Roboz GJ, Sekeres MA, Cluzeau T, Sweet KL, McLemore A, McGraw KL, Puskas J, Zhang L, Yao J, Mo Q, Nardelli L, Al Ali NH, Padron E, Korbel G, Attar EC, Kantarjian HM, Lancet JE, Fenaux P, List AF, Komrokji RS. Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes. J Clin Oncol. 2021 May.39(14):1584-1594. Pubmedid: 33449813. Pmcid: PMC8099410.
  • Jain MD, Zhao H, Wang X, Atkins R, Menges M, Reid K, Spitler K, Faramand R, Bachmeier CA, Dean EA, Cao B, Chavez JC, Shah BD, Lazaryan A, Nishihori T, Hussaini MO, Gonzalez RJ, Mullinax JE, Rodriguez P, Conejo-Garcia J, Anasetti C, Davila ML, Locke FL. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood. 2021 May.137(19):2621-2633. Pubmedid: 33512407. Pmcid: PMC8120145.
  • Eschrich SA, Teer JK, Reisman P, Siegel E, Challa C, Lewis P, Fellows K, Malpica E, Carvajal R, Gonzalez G, Cukras S, Betin-Montes M, Aden-Buie G, Avedon M, Manning D, Tan AC, Fridley BL, Gerke T, Van Looveren M, Blake A, Greenman J, Rollison D. Enabling Precision Medicine in Cancer Care Through a Molecular Data Warehouse: The Moffitt Experience. JCO Clin Cancer Inform. 2021 May.5:561-569. Pubmedid: 33989014. Pmcid: PMC8240785.